Richard G. Harris, MD, led a panel discussion on “Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19” for the Grand Rounds in Urology audience in July, 2020.
How to cite: Harris, Richard G. Langford, Timothy D. Saltzstein, Daniel R. Crawford, E. David. “Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19” July, 2020. Accessed Jul 2024. https://grandroundsinurology.com/panel-discussion-on-challenges-of-managing-androgen-deprivation-therapy-patients-during-covid-19/
Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19 – Summary:
Richard Harris, MD, President of LUGPA and CEO of UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology, about modifications to their ADT treatment regimens during COVID-19. Dr. Saltzstein discusses a typical case in his practice: men with high-risk, de novo prostate cancer that he does not plan on keeping on a lifetime course of ADT. In this case, he pairs ADT with IMRT in a 6-month depot formulation of an agonist to avoid frequent visits to the office. Dr. Langford’s practice is following a similar approach, switching from 3-month injections to 6 months. They also discuss telehealth solutions for minimizing patient visits, such as follow-ups for blood draws, PSA results, and prostatectomies, and further concur that CMS needs to move more quickly to make telehealth more accessible for physicians and patients.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
ABOUT THE AUTHOR
Richard Harris, MD, is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA cum laude from Washington University in St. Louis, Missouri. He then completed a year of graduate work in biological science at the University of Illinois in Chicago, followed by medical school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in clinical drug development and research on over 70 drug trials and has also been on the advisory board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is LUGPA’s President. He is a founding member, CEO, and President of UroPartners, LLC, the largest group of urologists in the Midwest.
Dr. Harris is an Assistant Clinical Professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction, and kidney stone disease. Dr. Harris is one of the few urologists skilled in cryotherapy for prostate cancer.
